Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesInfectious Agent Antigen DetectionCPT cpt-87812-sars-cov-2-and-influenza-a-b-antigen-immunoassay-visual
    Ask Trek AI about this page

    CPT 87812: Rapid Antigen Immunoassay for SARS–CoV–2 and Influenza A/B

    CPT code 87812 describes a laboratory immunoassay with direct optical (visual) observation to detect antigens for severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) and influenza A and B from a patient specimen, typically performed as a rapid diagnostic test on nasal or throat swab specimens; this is a point-of-care or laboratory-based rapid antigen immunoassay service commonly provided in outpatient clinics, urgent care centers, emergency departments, and clinical laboratories.

    For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.

    Customize your policy alerts

    Sign up for cpt 87812 policy alerts

    Get alerted when payer policies referencing 87812 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A symptomatic adult presents to an urgent care clinic in mid-winter with acute onset fever, cough, nasal congestion, and sore throat. A nurse collects a bilateral anterior nasal swab and delivers the specimen to the clinic laboratory. A lab analyst performs an immunoassay with direct optical (visual) observation to detect antigens for SARS–CoV–2 and influenza A/B using a CLIA-waived or moderate complexity point-of-care platform. The test result is read visually within the manufacturer-specified time window and documented in the electronic health record. Positive results prompt infection control measures and clinical management; negative results in a high-risk or high-suspicion patient may lead to molecular testing or repeat testing per clinical protocols. Typical site of service: outpatient clinic, urgent care, emergency department, or physician office laboratory; specimen: nasal or throat swab; service type: point-of-care antigen immunoassay.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    87804Infectious agent antigen detection by immunoassay, direct optical observation, single step method; respiratory syncytial virusPerformed alongside or in panels when testing for multiple respiratory viral antigens in symptomatic patients
    87426Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2, amplified probe techniqueUsed when a molecular confirmatory test is ordered after a negative or discordant rapid antigen test
    87813Infectious agent antigen detection by immunoassay, direct optical observation, multiplex for multiple viruses (e.g., SARS-CoV-2 and influenza)Alternative CPT code used when a multiplex kit explicitly covers multiple targets; relates directly as another coding option if applicable
    99000Handling and/or conveyance of specimen for transfer of special testing (may be payer-specific)Billed when specimens are transported to a reference lab for further testing
    36415Collection of venous blood by venipuncturePerformed if serologic testing or additional laboratory evaluation is required in the same visit

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    25CPT modifier 25 indicates that on the same day as another procedure or service, the same physician or other qualified health care professional provided a significant, separately identifiable…- When to apply: Use modifier 25 only on an E/M code to indicate the same provider delivered a significant, separately identifiable E/M service on the same day as another procedure or service — i.e.,…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    76Modifier -76, Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional, is appended when the same provider performs an identical, medically necessary procedure or…- Use modifier -76 when the same physician or other qualified health care professional performs an identical procedure or service a second (or subsequent) time on the same date of service and the…
    77Modifier 77 indicates that a previously performed procedure or service was legitimately repeated by a different physician or other qualified health care professional. The AMA’s CPT definition…- Use modifier 77 when a basic procedure or service already performed is repeated by a different physician or other qualified health care professional (for example, a second provider independently…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207Q00000X
    363L00000X
    208D00000X
    207R00000X
    208000000X
    2083B0002X
    2084N0402X
    171M00000X

    Related ICD-10-CM Codes

    26 rows

    ICD-10-CM CodeDescription
    B34.2Coronavirus infection, unspecified
    B34.9Viral infection, unspecified
    J00Acute nasopharyngitis [common cold]
    J01.90Acute sinusitis, unspecified
    J02.9Acute pharyngitis, unspecified
    J06.9Acute upper respiratory infection, unspecified
    J09.X1Influenza due to identified novel influenza A virus with pneumonia
    J10.1Influenza due to other identified influenza virus with other respiratory manifestations
    J11.1Influenza due to unidentified influenza virus with other respiratory manifestations
    J12.82Pneumonia due to coronavirus disease 2019

    Showing 1–10 of 26

    Related Payer Policy Updates

    Specialty: Infectious Disease1 / 3

    10 rows

    PolicyPayerEffective Date
    Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    HIV/AIDS Pharmacologic Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    Long-Acting Injectable Antiretroviral Agents for HIVColorado Rocky Mountain Health Plans2026-10-01
    B-Hemolytic Streptococcus TestingOscar Health2026-10-01
    Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance AssaysOscar Health2026-10-01
    Hepatitis Testing (A, B, C, D) Coverage CriteriaOscar Health2026-10-01
    Lyme Disease Testing Coverage CriteriaOscar Health2026-10-01
    Pathogen Panel TestingOscar Health2026-10-01
    Diagnostic Testing of Common Sexually Transmitted InfectionsOscar Health2026-10-01
    Testing for Vector-Borne InfectionsOscar Health2026-10-01

    Related Codes

    CPT-87260-ADENOVIRUS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87260: Adenovirus Antigen Detection by Immunofluorescence

    CPT-87265-BORDETELLA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87265: Bordetella Antigen Detection by Immunofluorescence

    CPT-87267-ENTEROVIRUS-DFA-ANTIGEN-DETECTION

    CPT 87267: Enterovirus Antigen Detection by DFA

    CPT-87269-GIARDIA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87269: Giardia Antigen Detection by Immunofluorescence

    CPT-87270-CHLAMYDIA-TRACHOMATIS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87270: Chlamydia trachomatis Antigen Detection by Immunofluorescence

    CPT-87271-CMV-DFA-ANTIGEN-DETECTION

    CPT 87271: CMV Antigen Detection by Direct Fluorescent Antibody

    CPT-87272-CRYPTOSPORIDIUM-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87272: Cryptosporidium Antigen Immunofluorescent Test

    CPT-87273-HSV-2-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87273: HSV-2 Antigen Detection by Immunofluorescence

    CPT-87274-HSV-1-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87274: HSV-1 Antigen Detection by Immunofluorescence

    CPT-87275-INFLUENZA-B-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87275: Influenza B Antigen Detection by Immunofluorescence

    Showing 1–10 of 167

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.